about
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allHIV-1 RNA genome dimerizes on the plasma membrane in the presence of Gag protein.Characterization, mapping, and distribution of the two XMRV parental provirusesStoichiometry of the antiviral protein APOBEC3G in HIV-1 virionsLikely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistanceMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels.Cytoplasmic HIV-1 RNA is mainly transported by diffusion in the presence or absence of Gag proteinDeoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rateRole of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity.Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switchingEffect of distance between homologous sequences and 3' homology on the frequency of retroviral reverse transcriptase template switching.A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinantsY586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts.Design of retroviral vectors and helper cells for gene therapy.Recombinant origin, contamination, and de-discovery of XMRVThe "Connection" Between HIV Drug Resistance and RNase HZinc finger domain of murine leukemia virus nucleocapsid protein enhances the rate of viral DNA synthesis in vivo.APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model.Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.Multiple barriers to recombination between divergent HIV-1 variants revealed by a dual-marker recombination assaySevere restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells.Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners.Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B.Mechanisms and factors that influence high frequency retroviral recombinationNucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.Recombinant origin of the retrovirus XMRV.Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis.Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.Dynamics of HIV-1 RNA Near the Plasma Membrane during Virus AssemblyConnection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceFunctional complementation of nucleocapsid and late domain PTAP mutants of human immunodeficiency virus type 1 during replication.
P50
Q26823568-2530886E-07F9-4A3D-B175-C949E6EABEBFQ27318140-5CD45631-517D-4F43-A46F-43E784E1BDDBQ28251595-184C3B79-F1F1-4191-A966-619C1BE4E053Q28275589-FD406068-7548-4971-8F04-C71448E710F6Q28475150-3C9CF889-2B1B-4943-B0E1-520EC0FE2133Q30381745-08D58492-FD8C-4E17-93A2-B6837A91B3F5Q30418789-9467D442-96A8-45E9-B5E9-1CAC66C3BBF0Q30606267-0C62E5A3-6C25-4483-9F4F-53C020A8B95DQ33784748-1159AECB-489C-4F88-8B52-4E4D8008F481Q33787219-E3AB01C6-9BFC-4588-B175-53B6EFDEA49AQ33809246-9E354668-8EA4-4B9E-8732-B4BC8E7BE4E7Q33818586-E9EA9638-4B42-4216-AE78-F7FC4226E43AQ33826904-7554D1CC-0669-440F-92D0-07165A67D6CAQ33826968-D1278003-8CA2-4692-A6D7-7547074F1E5AQ33877299-83B66C9E-6125-44DF-AB34-C0AE1C7D4DECQ33964088-495F4882-C229-4BB7-97C5-5D723FD9C0D2Q34059564-F1808D9B-C48B-4B4E-95AF-A22CA974F616Q34099109-CF4E8647-5316-43B9-8A60-AAB720E4ACEFQ34106405-219C2C85-566F-4A22-8013-7A30BBC38423Q34289436-ED5E31C1-D031-4976-B84E-355D20BA7205Q34313605-F8694EBC-B8C8-42EE-8008-A4DF0D5491A7Q34343761-049C29A3-F80D-4391-B62C-05B0B2A82F3AQ34352429-229FB80F-B123-4FBF-A110-25BAB1DC9291Q34416665-47C05A5B-BD70-4074-92C9-F43BD437088AQ34681252-7D2805E6-3960-426A-BE23-584F8C97FBFBQ34731376-F104D583-FA25-484E-B457-6806CBDD1C12Q35076674-15A44F6C-DE2A-4D4A-A655-FF8F2931C548Q35140343-A300B885-62A5-47CC-A17F-D3078395C92AQ35191547-874EE8D1-3C78-4C9F-891F-338BAD300AC7Q35192821-1EBC41BD-3CDE-4CEF-80F4-F62732550746Q35276750-5284E1EE-CCF4-4CFF-8D9D-60F9D33065D3Q35692310-AE839F4A-4342-42AB-BC0F-B535C6BACF35Q35755248-FDDF2999-3635-4E2B-87F9-1E18C186B8FBQ35857366-CD1667C3-D6F8-4509-AD87-65991AD4D25AQ35890587-1FD22E1F-8B89-4F2F-B412-AC08D7AB6384Q35947607-E75693A8-CD55-4BAD-B56D-113C2B2055CCQ35947612-C586ED06-27F5-40F7-BAAF-76F3D6EBD68DQ36208144-1A296D94-C2AE-45B3-B014-710609CF2F25Q36501787-EB7C4DAB-4F06-4D0A-BED2-0D3E88E46550Q36761995-FF1118C2-DFF6-4760-881E-47518815963E
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Pathak VK
@ast
Pathak VK
@es
Pathak VK
@nl
Vinay K. Pathak
@en
type
label
Pathak VK
@ast
Pathak VK
@es
Pathak VK
@nl
Vinay K. Pathak
@en
altLabel
Pathak VK
@en
prefLabel
Pathak VK
@ast
Pathak VK
@es
Pathak VK
@nl
Vinay K. Pathak
@en
P31
P496
0000-0003-2441-8412